Jubilant Ingrevia Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
JUBLINGREA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.2 pts less than Nifty Smallcap 250 and 3.6 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jubilant Ingrevia Limited reported audited consolidated financial results for FY26 with total revenue from operations at Rs 4,38,807 lakhs, up 5% from Rs 4,17,761 lakhs in FY25. Net profit increased 10.6% to Rs 27,791 lakhs from Rs 25,117 lakhs. Basic EPS improved to Rs 17.59 from Rs 15.89. Q4 FY26 revenue was Rs 1,17,865 lakhs (up 12% YoY) with net profit of Rs 8,644 lakhs. The company reported an exceptional item of Rs 1,304 lakhs due to one-time impact of new Labour Codes. Operating margin expanded to 8.92% from 8.65% in the prior year. The Board recommended a final dividend of Rs 2.5 per share, taking total FY26 dividend to Rs 5 per share. Auditors issued an unmodified (clean) opinion on the financial statements. The company also acquired Remidex Pharma Private Limited during Q4 for Rs 1,628 lakhs.
The company delivered steady profit growth with margin expansion, supported by a clean audit. The exceptional labour code charge is non-recurring and does not affect underlying business performance. The healthy debt-equity ratio of 0.19 and strong cash generation from operations (Rs 52,427 lakhs) indicate solid financial health for shareholders.